^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Serine protease inhibitor

    Related drugs:
    9d
    A Randomized Control Trial Assessing the Effect of Topical Tranexamic Acid on Risk of Hematoma in Breast Surgery (clinicaltrials.gov)
    P4, N=107, Completed, University of Michigan | N=500 --> 107
    Enrollment change
    16d
    Multifaceted anticancer activity of nafamostat mesylate in human fibrosarcoma: first evidence of mitochondrial apoptosis and suppressed MMP-2/-9 mRNA expression. (PubMed, BMC Pharmacol Toxicol)
    This study provides the first evidence that nafamostat mesylate exerts multifaceted anticancer effects in HT1080 fibrosarcoma cells, targeting proliferation, migration, apoptosis, and invasion. These findings support the potential repurposing of nafamostat mesylate as a therapeutic agent for fibrosarcoma and warrant further preclinical investigations to evaluate its translational applicability.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • ANXA5 (Annexin A5)
    |
    nafamostat
    1m
    Comparison of the efficacy and safety of nafamostat mesylate and heparin in blood purification therapy for patients with severe acute pancreatitis: A randomized controlled trial (ChiCTR2500111161)
    P4, N=140, Not yet recruiting, Weifang People's Hospital; Weifang People's Hospital
    New P4 trial
    |
    nafamostat
    1m
    Effect of infusion of tranexamic acid at different drip rates on the incidence of nausea and vomiting in patients undergoing lumbar interbody fusion via transforaminal approach: a prospective, double-blind, randomised controlled clinical study protocol (ChiCTR2500110270)
    P4, N=180, Not yet recruiting, West China Tianfu Hospital, Sichuan University; Sichuan University West China Tianfu Hospital
    New P4 trial
    1m
    The Safety and Efficacy of Different Anticoagulation Strategies in Double Filtration Plasmapheresis Therapy (ChiCTR2500109547)
    P=N/A, N=300, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New trial
    |
    nafamostat
    1m
    Clinical research on nafamostat mesylate for injection (ChiCTR2500107352)
    P3, N=220, Not yet recruiting, The Second Affiliated Hospital of Nanjing Medical University; The Second Affiliated Hospital of Nanjing Medical University
    New P3 trial
    |
    nafamostat
    1m
    Efficacy Study of Intradermal Injection of Tranexamic Acid at Different Concentrations for the Treatment of Melasma and Post-Inflammatory Hyperpigmentation After Phototherapy (ChiCTR2500109099)
    P=N/A, N=120, Recruiting, Plastic Surgery Hospital, Chinese Academy of Medical Sciences; Plastic Surgery Hospital, Chinese Academy of Medical Sciences
    New trial
    1m
    IVTXA: Investigating the Use of Intravenous Tranexamic Acid in Gender Affirming Mastectomy (clinicaltrials.gov)
    P2, N=150, Recruiting, University of California, San Francisco | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2025 --> May 2026
    Trial completion date • Trial primary completion date
    2ms
    A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems (clinicaltrials.gov)
    P=N/A, N=500, Recruiting, Takeda | N=1000 --> 500
    Enrollment change
    2ms
    NEPHRO: Nafamostat Efficacy in Phase 3 Registrational CRRT Study (clinicaltrials.gov)
    P=N/A, N=70, Recruiting, Talphera, Inc | N=166 --> 70
    Enrollment change
    |
    nafamostat
    2ms
    The Effect of Local and Systemic Tranexamic Acid on Edema and Ecchymosis in Orbital Surgery (clinicaltrials.gov)
    P4, N=150, Suspended, Montefiore Medical Center | Recruiting --> Suspended
    Trial suspension
    2ms
    NEPHRO: Nafamostat Efficacy in Phase 3 Registrational CRRT Study (clinicaltrials.gov)
    P=N/A, N=166, Recruiting, Talphera, Inc | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    nafamostat